The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as the launch of DDW’s latest In Focus report. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers three articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Medicinal cannabis: Why more clinical trials and better access is needed, What are the opportunities for decentralised clinical trials?, and Choosing the right site solution for clinical trials. In the first article, Michael Sassano, CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. In the second article, Tom Brazier, Director, Decentralised Clinical Solutions, mdgroup and Stephanie Larimer, Q² Solutions discuss the opportunities for decentralised clinical trials and how common pitfalls can be avoided through communications and streamlined working. In the third article, Independent Medical Writer Leonie Onslow explores the challenges of traditional clinical trial models and how to improve recruitment and retention.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of cell therapy research findings revealed at EHA2024. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack of all trades, master of…many. In the first article, Imran Haque, VP Data Science at Recursion, describes the journey of the AI platform that predicted the efficacy of repurposed drugs for Covid-19 In the second article, Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation to CAR-T therapies. You can listen to the DDW podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology candidate, and a plant-based therapy for diarrhoea. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “The future climate and landscape for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Pharma’s important climate and What will the 2023 drug discovery landscape look like? In the first article, DDW Editor Reece Armstrong comments of the impact of climate change in the drug discovery sector. In the second article, DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which 2023 will lean.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Tien Lee, CEO of Aardvark Therapeutics, a San Diego-based biotech company in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut unlike GLP-1 which is systemic. The drug targets receptors in the gut where it triggers cholecystokinin (CCK), a GI system peptide hormone responsible for stimulating the digestion of fat and protein. CCK stimulates pancreatic secretion and gallbladder contraction, regulation of gastric emptying, and sends a signal to the brain that one has had enough to eat. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.